

Financial Tear Sheet

Corporate Profile

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. Fibrocell's most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of vocal fold scarring resulting in chronic or severe dysphonia. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin and joint diseases using genetically-modified autologous fibroblasts. Fibrocell is in preclinical development of FCX-007, its orphan gene-therapy product candidate, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in preclinical development of FCX-013, its gene-therapy product candidate, for the treatment of linear scleroderma. In addition, Fibrocell and Intrexon will be commencing preclinical development of a gene therapy for the treatment of chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions

Stock Information

FCSC (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$2.47
Change (%)	▼ 0.03 (1.20%)
Volume	10,180
52 Week Low	\$1.57
Market Cap	\$36,351,400
Rolling EPS	-1.95
PE Ratio	N/A
Shares Outstanding	14,717,166

Data as of 08/18/17 4:00 p.m. ET



Recent Headlines & Events

08/09/17 - 8:01 a.m.
Fibrocell Reports Second Quarter 2017 Financial Results and Recent Highlights

08/03/17 - 8:00 a.m.
Fibrocell to Present at Canaccord Genuity 37th Annual Growth Conference

Date	Title
09/11/17 9:10 a.m. ET	Fibrocell at Rodman & Renshaw 19th Annual Global Investment Conference Location New York, NY

08/02/17 - 8:00 a.m.
 Fibrocell to Host Conference Call and Webcast on Wednesday, August 9, 2017 to Discuss Second Quarter 2017 Financial Results and Recent Operational Highlights

09/14/17 3:15 p.m. PT **Fibrocell at Global Genes' 2017 RARE Patient Advocacy Summit**
Location Irvine, CA

10/04/17 through 10/06/17 **Fibrocell at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa**
Location La Jolla, CA

SEC Filings

Filing Date	Form
08/09/17	10-Q
08/09/17	8-K
06/27/17	8-K
06/26/17	4

Corporate Governance

Douglas J. Swirsky	Chairman of the Board
Julian P. Kirk	Director
Marc B. Mazur	Director
John Maslowski	Director
Kelvin D. Moore	Director
Marcus E. Smith	Director
Christine St.Clare	Director

Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	41	32.09	54.5	8,022,804
Mutual Fund	16	5.05	8.6	1,259,562
Director and Officer	1	.25	0.7	105,600

*Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
Third Security, LLC	5,540,140	37.6	0	06/30/17
Fidelity Management & Research Company	850,214	5.8	-18,598	06/30/17
MSD Partners, L.P.	692,960	4.7	0	06/30/17
The Vanguard Group, Inc.	346,576	2.4	-47,690	06/30/17
Renaissance Technologies LLC	108,264	0.7	21,400	06/30/17
Creative Planning, Inc.	61,090	0.4	48,755	06/30/17
Geode Capital Management, L.L.C.	58,710	0.4	-1,717	06/30/17
Parametric Portfolio Associates LLC	48,259	0.3	35,000	06/30/17
BlackRock Institutional Trust Company, N.A.	41,128	0.3	-25,683	06/30/17
California Public Employees' Retirement System	36,333	0.3	0	06/30/17

Data provided by Nasdaq. Minimum 15 minutes delayed.